Week in Review: The Latest from PhRMA

Priscilla VanderVeer
Priscilla VanderVeer July 31, 2015

Week in Review: The Latest from PhRMA.

Share This

Medicare: Medicare celebrated its 50th anniversary this week! To note the occasion, we looked at the continued success of Part D, which helps many older Americans and people living with disabilities:

  • Learn from patients themselves about how Part D helps them in a new video.
  • Find out about the more than 435 medicines in development for older Americans.
  • Get more information about how average monthly premiums for 2016 Part D plans will remain relatively stable, just as they have since 2011.

week-in-reviewFact Check Fridays: Today we launched “Fact Check Fridays,” a series we’ll be using to separate truth from fiction and set the record straight. This week’s fact-check: the truth about inter partes review (IPR) and patent litigation reform.

Drug Price Control Proposals: In case you missed it, the Community Oncology Alliance spoke out against the drug-price control recommendations published in the Mayo Clinic Proceedings. Learn more here.

Health Spending Projections: New National Health Expenditure projections released by the Centers for Medicare & Medicaid Services challenges claims about the sustainability of prescription drug spending. Even with new treatments for hepatitis c, high cholesterol and cancer, spending on retail prescription Medicines are projected to remain approximately 10 percent of U.S. health care spending through 2024. Learn more here.

No Two Patients are the Same: Every patient is different and only some can control their high cholesterol through better adherence and lifestyle changes. Take a look at our new patient profiles, George and Betty, to learn more.

Stop Abuse of Biopharmaceutical Patents: John Castellani, President and Chief Executive Officer of PhRMA, and James Greenwood, President and Chief Executive Officer of Biotechnology Industry Organization (BIO), outline a clear path forward for reform of patent legislation to eliminate abuse to biopharmaceutical patents in an op-ed published in The Hill and a joint letter to the Senate Judiciary Committee. Subsequently, a letter signed by 79 Members of Congress was sent to House leadership emphasizing how critical reform is for the full spectrum of industry. Check it out here.